tirzepatide eu FDA Grants a New Indication for Obesity Management FDA Approves Lilly's Zepbound™ (tirzepatide)

It also draws on Telegra MD's own Terms of Service (telegramd.com/terms-of-service/, reviewed directly), current FDA and HHS reporting on testosterone, enclomiphene, gonadorelin, and anastrozole regulatory status (including the February 2025 FDA labeling action and the June 2026 HHS-announced request to remove the age-related "Limitation of Use"), and Endocrine Society clinical practice guidance on testosterone therapy

The same rebound effect has been seen with other chronic conditions (e.g., diabetes, etc.) that the GLP1 receptor agonist may have been managing

Cutting fluids 2 hours before bed often helps

2005;11:CR2969 16

What the Remaining 2026 Readouts Mean for the Timeline The trials that drive the commercial obesity label are TRIUMPH-1 (general obesity) and TRIUMPH-3 (obesity plus cardiovascular disease)

While this has not been observed in humans at standard doses, and microdoses are far below standard doses, patients with existing thyroid conditions (including Hashimoto) should have regular thyroid monitoring